Knight Therapeutics | GUD - Selling And Administration Expenses

Stock Price
7.54
Daily Change
0.08 1.07%
Monthly
6.05%
Yearly
27.80%
Q2 Forecast
7.49

Knight Therapeutics reported CAD35.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Cronos Group USD 19.45M 4.9M Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
IQVIA Holdings USD 468M 46M Dec/2025
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 308M 40M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Organigram Holdings CAD 7.73M 1.13M Dec/2025
Organon & Co USD 399M 54M Sep/2025
Revvity USD 251.73M 9.82M Dec/2025
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 1.03B 144.1M Dec/2025
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025